A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
Completed
Forest Laboratories
Phase 4
2014-11-18
This study evaluates the efficacy, safety and tolerability of levomilnacipran
extended-release (ER) compared with placebo in the prevention of depression relapse in major
depressive disorder (MDD).
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Completed
Forest Laboratories
Phase 3
2015-06-23
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major
Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK)
data to guide dose selection for future pediatric studies of levomilnacipran.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
